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Abstract
Intact synaptic function and plasticity are fundamental prerequisites to a healthy brain. Therefore, synaptic proteins are one
of the major targets for drugs used as neuro-chemical therapeutics. Unfortunately, the majority of drugs is not able to cross
the blood–brain barrier (BBB) and is therefore distributed within the CNS parenchyma. Here, we report the development of
novel biodegradable Nanoparticles (NPs), made of poly-lactide-co-glycolide (PLGA) conjugated with glycopeptides that are
able to cross the BBB and deliver for example Zn
2+ ions. We also provide a thorough characterization of loaded and
unloaded NPs for their stability, cellular uptake, release properties, toxicity, and impact on cell trafficking. Our data reveal
that these NPs are biocompatible, and can be used to elevate intracellular levels of Zn
2+. Importantly, by engineering the
surface of NPs with antibodies against NCAM1 and CD44, we were able to selectively target neurons or glial cells,
respectively. Our results indicate that these biodegradable NPs provide a potential new venue for the delivery Zn
2+ to the
CNS and thus a means to explore the influence of altered zinc levels linked to neuropsychological disorders such as
depression.
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Introduction
The majority of drugs used as neuro-chemical therapeutics
target synaptic proteins. Unfortunately, a high number of drugs
are not able to cross through the blood–brain barrier (BBB) [1].
The transmissivity of this epithelial structure is restricted by the
presence of tight junctions (TJ) that connect the cerebral
endothelial and epithelial cells of the choroids plexus. Additionally,
glial cells are found surrounding the surface of the capillaries,
which cohere the endothelial cells, producing an electrical
resistance much higher than that of other systemic endothelia
[2]. Recent studies have demonstrated a non-invasive method of
drug delivery to the CNS, based on the use of biodegradable
Nanoparticles (NPs). Injectable nanoparticulate drug carriers
made of poly-lactide-co-glycolide (PLGA), and specifically mod-
ified with ligands were shown to be able to cross the blood–brain
barrier (BBB), thus representing an important potential tool for
treatment of neurological diseases [3,4].
Inparticular,thisnewstrategyforNPs-braintargetingisbasedon
the surface engineering of NPs, using a glycopeptides (g7)–derived
PLGA [3,5,6].The attachment of ligands for CNS targeting and/or
fluorescent markers on the surface of NPs allows evaluating and
influencingtheirpropertiesbothinvitroandinvivo.Theseengineered
NPs(BBB-NPs)bearthepossibility to deliver differentkindsof drugs
to the brain with a high rate of efficiency (13–15% of the injected
dose) [7]. Thus, by encapsulation of drugs into BBB-NPs a
significant improvement of brain delivery can be expected.
In recent years, there has been mounting evidence that suggests
a correlation between zinc deficiency and clinical depression [8,9].
Clinical studies as well as work with animal models indicate that
zinc levels and some neuropsychological disorders are functionally
linked. Zinc deficiency, for example, has been shown to induce
depression- and anxiety-like behaviors, while zinc supplementation
has been used to treat depression. Intriguingly, zinc administration
improves the efficacy of antidepressant drugs in depressed patients
[10] and the level of zinc at synapses in the hippocampus [11].
Thus, while zinc deficiency may have a critical role in the
development of mood disorders and may serve as a putative model
of depression in mice, zinc supplementation may be important in
the treatment of these disorders [12].
Given the therapeutic potential of NPs, in the present study, we
have investigated whether un-modified PLGA NPs (P-NPs) or
BBB-NPs specifically targeted to neurons or glia cells could be
used to encapsulate and deliver Zn
2+ into cells. Our data
demonstrate that this strategy is feasible creating a novel platform
not only for understanding the role of zinc in neuronal function,
but also the delivery of drugs into the CNS and ultimately the
treatment of neurological diseases.
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NPs do not affect cell viability or neuronal
morphogenesis
Although in previous studies, NPs have been shown to cross the
BBB, whether they are actively taken up by neurons and/or
adversely affect cell viability is poorly investigated. To explore
these possibilities, we examined the effect of adding NPs to
dissociated neuronal/glial cultures. In an initial set of experiments
designed to assess their affect on cell viability, cultures were treated
with one of four preparations [unloaded P-NPs, unloaded BBB-
NPs, Zn
2+ loaded P-NPs (Zn-P-NPs) or Zn
2+ loaded BBB-NPs (Zn-
BBB-NPs)] starting at DIV7 (625 mg NPs per ml) (Fig. 1A) and
compared to untreated control cells at DIV14.
Cells treated with unloaded P-NPs and BBB-NPs exhibited no
difference in their morphology, e.g. dendrite branching measured
by determining the ‘‘dendritic complexity index’’ DCI [13] or the
number of synapses per unit length of dendrites (Fig. S1). The
findings also allow to dismiss the possibility of a possible toxic effect
of glycopeptides covering NPs surface (BBB-NPs) since there is no
significant difference between viability-results with empty P-NPs
and empty BBB-NPs. Furthermore, the number of neurons
assessed by anti-MAP2 staining as well as overall cell number
per field of view including glial cells assessed by DAPI staining was
not changed compared to control cells. Cells treated with NPs
containing Zn
2+ (Zn-P-NPs and Zn-BBB-NPs) show a slight but
significant reduction in glial and/or neuronal cell number
following the addition of Zn-BBB-NPs or Zn-P-NPs, respectively.
Since cells treated with empty P-NPs do not show this decrease in
neurons, the effect is likely due to an increase in intracellular zinc
levels and not by the treatment with NPs itself. The intracellular
zinc concentration might have reached already toxic levels for
neurons but not for glial cells (Zn-P-NPs) or both, neurons and
glial cells (Zn-BBB-NPs) due to increased cellular uptake of Zn-
BBB-NPs (Fig. 1A).
To further investigate the influence of NPs on cell viability, cells
were plated with a density of 20,000 cells per coverslip and treated
with different NP concentrations of ‘‘P-NPs’’ and ‘‘BBB-NPs’’, i.e.
Ctrl (625 mg NPs per ml), 26,4 6, etc. compared to the
concentration used in the first cell viability experiment (Fig. 1B).
The cells were fixed at DIV14 and the number of cells was
assessed. Beginning with the 66 concentration, the standard-
deviation becomes larger, meaning that there were already some
optic fields per/coverslip, where cell viability was reduced while in
other regions cells remained healthy. However, at 86 (‘‘BBB-
NPs’’) and 106(‘‘P-NPs’’ and ‘‘BBB-NPs’’) concentrations of NPs,
there is a significant reduction in cell number in all fields of view.
Neurons and glial cells endocytose nanoparticles
To explore the fate of NPs added to our neuronal/glial cultures,
we took advantage of the fluorescent labeling of both unloaded P-
NPs and BBB-NPs (by using tetra-methyl rhodamine conjugated
PLGA in the formulation of the NPs). The results reveal that
unloaded P-NPs and BBB-NPs readily associated with cultured
cells (Fig. 2A). Interestingly, BBB-NPs were found associated to
cells in higher amount compared to P-NPs (Fig 2A), perhaps due
to the presence of the glycopeptides coating on the surface of BBB-
NPs. To investigate whether cells take up NPs, we used Zn
2+
loaded NPs and Zinpyr-1, a zinc staining fluorophore, to visualize
intracellular zinc-ions. Interestingly, in contrast to untreated as
well as ZnCl2 supplemented cells (data not shown), bright
fluorescent vesicular structures were visible in HEK293 cells and
hippocampal neurons (Fig. 2B, arrows and Fig. S2A) after
supplementation of the growth medium with Zn
2+ loaded Zn-P-
NPs or Zn-BBB-NPs (data not shown). Monitoring the distribution
of the rhodamine-conjugated PLGA, we observed a strong
colocalization with Zinpyr-1 fluorescent puncta. These data are
consistent with the internalization of NPs into Zn
2+ rich
intracellular organelles/vesicles (Fig. 2C). This conclusion is
furthermore consistent with the selective co-localization of the
zinc signal with fluorescently tagged Zn-BBB-NPs treated cells
(Fig. 2C, full arrows) but not cells treated with unloaded BBB-NPs
(Fig. 2C, empty arrows).
In order to study the mechanism of entrance and the
localization of BBB-NPs within cells, we used fluorescent BBB-
NPs together with FM1-43FX dye (Fig. 2D). FM1-43FX is a
fixable membrane probe widely used for monitoring recycling
vesicles [14]. In these experiments, fluorescently labeled BBB-NPs
(Fig. 2D) and P-NPs (Fig. 2E) were found to decorate the same
vesicular structures labeled with FM1-43FX consistent with the
model of NPs entering cells by endocytosis (Fig. 2A,D,E). Analysis
of the amount of vesicles harboring NPs compared to the total
pool of labeled vesicles shows that no differences between P-NPs
and BBB-NPs can be seen. However, the total number of FM1-
43FX+NP positive vesicles was significantly increased in BBB-NP
treated cells (Fig. 2E). These findings suggest that the PLGA
coating might enhance endocytosis of NPs. Additionally, we
monitored the fluorescent pattern of BBB-NPs treated cells over a
time-course of 7 d. This revealed that the initial punctate pattern
becomes more diffuse over time, consistent with the slow
degradation of BBB-NPs resulting in cells with higher background
fluorescence (Fig. S2B).
Taken together, these data indicate that BBB-NPs have the
capacity to release their content intracellularly.
Characterization of Zn
2+ loaded NPs
As a biodegradable polymer, NPs are predicted to slowly release
their content over time. We were thus keen to characterize the rate
of zinc release both in vitro and in vivo. For all studies outlined
below, batches of NPs were characterized for their size, surface
charge and general shape by means of Photon Correlation
Spectroscopy (PCS) methods and SEM analysis. All NPs
(independently from the surface modifiers or the loading) show
an average size of 190–210 nm, with overall surface charge
(expressed as zeta-potential, z-p) close to neutrality (z-p ranging
from 20.5 to 210 mV). This value was maintained also after re-
suspension of all kinds of lyophilized NPs. Moreover, a study on
the content and release in 7.4 pH buffer was performed on Zn
2+-
loaded P-NPs (Zn-P-NPs) and BBB-NPs (Zn-BBB-NPs) evidencing
a mean of 2.6 mg of Zn
2+ (detected both by colorimetric and
atomic absorbance technologies) per 100 mg of NPs. Moreover,
surface analysis (i.e. ESCA analysis) of the antibody-engineered
NPs (Anti-NCAM1-NPs and Anti-CD44-NPs) demonstrated the
efficacy of the surface modification process.
Characterization of the in vitro release of Zinc from NPs
ZnSO4.7 H 2O was encapsulated in both P-NPs and BBB-NPs
(mean size close to 200 nm, PDI of 0.204 and a z-p of 26.13 mV)
with a final content of 2.6 mg of Zn
2+-ions per 100 mg of NPs.
Both NP samples showed similar features (with respect to loading
and chemico-physical properties). To assess the timescale, in which
Zn-P-NPs and Zn-BBB-NPs release Zn
2+ in vitro, both types of Zn-
loaded NPs were suspended in Neurobasal Medium +Glutamine
+B27 (NB++). A 1.5 mM basic Zn
2+ concentration of NB++ was
measured using plasma mass-spectrometry.
A suspension with an amount of Zn-loaded NPs (Zn-P-NPs and
Zn-BBB-NPs) approx. encapsulating 1 mM Zn
2+ was prepared,
added to the medium and incubated for 28 days at 37uC. Each
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(C46H36Cl2N6O5) a fluorescent sensor for Zn
2+ with a high
specificity and affinity for Zn
2+ (Kd=0.760.1 nM) (Fig. 3). Since
Zinpyr-1 is not able to enter or to be adsorbed by NPs, the rise in
fluorescence is due to NP-Zn
2+ release, a value that correlates
directly. After 28 days, TPEN (N,N,N9,N9-Tetrakis(2-pyridyl-
methyl)ethylenediamine) was added to the samples. TPEN is a
water-soluble and cell membrane permeable zinc chelator with
very high affinity for Zn
2+ (Kd for Zn
2+ binding to TPEN is 6.3 *
10
216 M at pH 7.6). A drop in fluorescence shows that the
fluorescence of Zinpyr-1 indeed was due to the presence of Zn
2+ in
the medium. Since Zinpyr-1 only fluoresces upon binding Zn
2+,
the loss of Zn
2+ due to chelation causes this drop in fluorescence.
The results of the release of Zn
2+ suggest that Zn-P-NPs and Zn-
BBB-NPs degrade over time, producing a sustained release: in
particular, during the first 16 days, a slightly faster release of Zn
2+
is visible compared to day 16–22, while, after 22 days, nearly all
Zn
2+ is released (Fig. 3). The release profile could be due to a
degradation/diffusion process happening on NPs architecture.
Since the release of Zn
2+ from both types of NPs is almost the
same, we chose to show only the release of Zn-P-NPs, in order to
avoid overlapping and redundancy of results.
Figure 1. Cell viability after treatment with NPs. A) Mixed neuronal cultures containing glia cells and hippocampal neurons were plated and
grown until DIV14. Cells were treated with the following NPs: ‘‘P-NPs’’ (empty NPs without ligand), ‘‘BBB-NPs’’ (un-loaded g7 ligand coated NPs), ‘‘Zn-
P-NPs’’ (NPs encapsulating Zn
2+) or ‘‘Zn-BBB-NPs’’ (g7 ligand coated NPs encapsulating Zn
2+) (all: 625 mg NPs per ml), at DIV7. Upper panel: cells were
stained with antibodies against the dendritic microtubule associated protein MAP2 and DAPI. The number of neurons (MAP2 positive cells) and the
overall cell number (DAPI staining) per optic field was measured. Neither P-NPs nor BBB-NPs affected cell number as quantified in the lower panel. A
small but significant reduction in cell number was observed in Zn-NPs (neurons) and Zn-BBB-NPs treated cells. B) Neuronal/glial cultures were plated
at 20,000 cells per coverslip and treated for 7 days with different concentrations of P-NPs and BBB-NPs (e.g. multiples of 625 mg NPs per ml applied to
control cells (Ctrl)). The cells were treated at 7DIV fixed at DIV14 and labeling for MAP2 and nuclei (DAPI) was performed. Lower panel: quantification
of DAPI positive cells/optical field of view (406 mag). Only healthy nuclei were counted. At 106 625 mg/ml (6.25 mg/ml), there is a significant
reduction in cell number of cells treated with P-NPs. Cell-number reduction with BBB-NPs treated cells is seen at 86625 mg/ml (5 mg NP/ml). Arrows
indicate neurons that underwent cell death.
doi:10.1371/journal.pone.0017851.g001
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To assess whether an intracellular environment alters the time
release properties of NPs, we monitored changes in intracellular
Zn
2+ in HEK293 cells and Hippocampal neurons treated with
NPs loaded with Zn
2+ (Zn-P-NPs and Zn-BBB-NPs). As above, the
Zinpyr-1 fluorescent probe was loaded into cells by its addition to
the culture medium. Zinpyr-1 is able to penetrate cell membranes.
In initial experiments, we examined the rate of intracellular
NPs-Zn
2+ release in HEK293 cells, a wildly used fibroblast cell line
that shares many properties of immature neurons [11]. Here,
HEK293 cells were incubated with a 30 mM ZnCl2 solution and a
suspension of Zn-P-NPs and Zn-BBB-NPs (End concentration:
1m MZ n
2+ after NP degradation in DMEM) (Fig. 4A,B). A final
zinc concentration was calculated using grey values of Zinpyr-1
fluorescence correlating to the local zinc concentration. The
background fluorescence of untreated HEK293 cells was subtract-
ed and cells treated only with 30 mM ZnCl2 used as reference (Fig.
S4). After 3 days, a final zinc concentration of 180 mM released by
Zn-BBB-NPs was reached (Fig. 4A,B). Compared to the expected
Zn
2+ release-curve (Fig. 3), this concentration should have been
reached only after 6–7 days. Thus, compared to in vitro release of
Zn
2+ from NPs, the release appears to occur faster in cells. This
might be due to a faster degradation of intracellular NPs. In line
with this, Zn-BBB-NPs that show increased cellular uptake
compared to Zn-P-NPs also lead to a significantly higher increase
of the intracellular zinc concentration after 1 d. Not unexpectedly,
after 3 days, HEK293 cells showed signs of distress and underwent
cell death. This is consistent with published literature showing that
an intracellular free zinc concentration of this magnitude is cyto-
toxic [15,16] (and Fig S3).
Zinc release in rat hippocampal neurons
In a parallel set of cell-based experiments, we investigated the
extent of Zn
2+ release from NPs in Hippocampal neurons. As
above, cells were incubated with a 30 mM ZnCl2 solution as zinc-
loading control (Fig. S4) and a suspension of Zn
2+ loaded NPs (Zn-
Figure 2. Subcellular localization of NPs in HEK293 cells and neurons. A) Images of hippocampal cultures treated with NPs (left panel).
Nanoparticles without ligand (P-NPs) or coated with BBB-ligand (BBB-NPs) associate with cells. The distribution pattern is consistent with NPs botho n
the surface and within cells. Quantification of Rhodamine fluorescent signals per cells shows a ratio of BBB-NPs to P-NPs of 3.15 (n=10) (right panel).
B) Changes in the intracellular zinc levels of HEK293 (upper panel) and neuronal (lower panel) cells after addition Zn-P-NPs were detected by loading
cells with Zinypr-1. Bright fluorescent vesicular structures were visible (arrows) in HEK293 cells as well as hippocampal neurons after application of Zn-
P-NPs compared to untreated (control) cells. The bottom row of images in each panel shows heat maps revealing regional differences in zinc levels.
C) Fluorescent images of HEK293 (upper panels) or neurons (lower panel) assessing the relative distribution of NPs and zinc. Zinypr-1 was used to
detect Zn
2+, and Rhodamine fluorescence to detect the distribution of Rhodamine labeled NPs. The zinc-signal colocalizes with fluorescent NPs in Zn-
BBB-NPs treated cells (HEK293: middle panel, full arrows and Neurons: lower panel) but not in unloaded BBB-NPs (empty arrows, upper panel). D)
Fluorescent images of glial cells (upper panel) and hippocampal neurons (lower panel) treated with Rhodamine-conjugated BBB-NPs and FM1-34FX.
BBB-NPs fluorescence is observed colocalizing with FM1-43 FX within endocytotic vesicles (arrows). E) Fluorescent P-NPs can - similar to BBB-NPs - be
found inside the cell soma co-localizing with FM 1-43 FX within endocytotic vesicles. Quantitative analysis of the percent of vesicles colabeled with
NPs and FM dye in comparison to the total pool of FM-labeled vesicles reveals that no significant differences between P-NPs and BBB-NPs can be
measured. However, the total number of FM/NP vesicles is significantly increased in BBB-NP treated cells vs. P-NP treated cells.
doi:10.1371/journal.pone.0017851.g002
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2+ after
NP degradation in Neurobasal +B27, +Glut) (Fig. 4C,D). To
maintain cell viability and ensure the growth and maturation of
primary hippocampal culture cells for 14DIV, the amount of NPs
loaded was reduced compared to the solution taken for HEK293
cells. Although the local Zn
2+ concentration at synapses after
synaptic activity can reach 300 mM, prolonged exposure to high
free Zn
2+ concentration causes cell death [15–17]. This is nicely
illustrated in supplemental data where we find that neurons are
more sensitive to free Zn
2+ compared to HEK293 cells, however
concentrations higher than 160 mM lead to cell death in both cell
cultures (Fig. S3).
In these experiments, the background and 30 mM ZnCl2
fluorescence was measured at 7DIV and 14DIV and since no
difference was obtained (Fig. S4), the average is used for the
quantification of intracellular Zn
2+ elevation (Fig. 4C,D). After
application of Zn
2+ loaded NPs, neurons display an increase in
intracellular zinc concentration. The zinc level can be reduced by
replacing the growth medium with medium without NPs (data not
shown). This leads to Zn
2+ efflux due to lower extracellular Zn
2+
concentrations in the culture medium (0.093 mgZ n
2+/
ml=1.42 mM for Neurobasal medium with addition of B27,
Pen/Strep and Glutamine measured by Plasma-Massspectrome-
try). As in HEK293 cells, Zn-BBB-NPs in neuron elicits a higher
intracellular level of zinc compared to Zn-P-NPs treated cells
(Fig. 4D).
Targeting Nanoparticles to specific neural cell
populations
Based on these experiments, it can be assumed that the
endocytosis of un-modified NPs (P-NPs and BBB-NPs) in the CNS
will occur in neurons as well as glial cells. However, a more
targeted drug release may be desired. Given that P-NPs can be
modified with almost any combination of ligands, we explored the
possibility of achieving cell type specific targeting. As a proof
principle experiment, we coupled NCAM1 and CD44 antibodies
to the surface of NPs that recognize antigens on the surface of
neurons and glia, respectively. As a control for antibody specificity,
neuronal cultures were immuno-stained with antibodies against
NCAM1, CD44 and MAP2 a neuronal specific microtubule
associated protein. As expected, NCAM1 antibodies immuno-
labeled MAP2 positive cells, whereas CD44 antibodies labeled glia
cells (Fig. 5A).
We then applied fluorescent NPs conjugated with anti-NCAM1
(anti-NCAM1-NPs) or anti-CD44 antibodies (anti-CD44-NPs) to
primary mixed hippocampal cultures to evaluate their targeting
behavior in presence of both, glia and neuronal cells (Fig. 5B). As
expected, control NPs without further modification (CNT-Ab-
NPs) associated with glial cells and neurons to a similar degree
(Fig. 5C). However, anti-NCAM1-NPs (NCAM-NPs) show
reduced targeting to glial cells together with highly increased
targeting to neurons stained for MAP2 (arrow Fig. 5B middle
panel and C). In contrast, anti-CD44-NPs (CD44-NPs) show
increased targeting to glial cells stained for Glial fibrillary acidic
protein (GFAP) together with decreased targeting to neurons
(arrow Fig. 5B lower panel and C). Interestingly, the anti-CD44
ligand not only increases targeting to glial cells, but appears to
promote the endocytosis of NPs.
Discussion
Non-invasive CNS drug delivery systems have been actively
studied, especially with the development of colloidal carriers such
as nanoparticles (NP) and liposomes. Indeed, reports in the
literature show that these carriers if properly engineered, with a
diameter around 100–200 nm, are able to cross the BBB without
apparent damage [18], and can deliver drugs or genetic material
into the brain [19,20]. However, a selective biodistribution within
the CNS is highly needed and this goal is far from being achieved.
Nowadays, the use of a polymeric NP is one of the most promising
approaches for CNS drug delivery [18,21,22], because polymeric
NPs possess advantages with respect to free drug molecules or pro-
drugs, such as a high drug-loading capacity [22]. In addition, NPs
protect the embedded drugs against chemical or enzymatic
degradation, thus increasing the chance for the active molecule
to reach the target site. Only few polymers currently guarantee the
safety of the polymer-based nanocarriers. Polylactide-co-glycolide
(PLGA) or polylactide (PLA) polymers are biodegradable,
biocompatible, FDA-approved and are therefore two of the most
promising polymers for the preparation of NPs [18]. In this paper,
Figure 3. NPs release Zn
2+ over time. Quantification of the rate of zinc released from NPs in vitro by monitoring free zinc levels with Zinypr-1
fluorescence. The blue line indicates the trend-line for the obtained data-points. The green line shows an overall drop of fluorescence after treatment
with TPEN that competitively binds free zinc with higher affinity. The fluorescence intensity of Zinpyr-1 was measured every 24 hrs and correlated to
the fluorescence of medium with known zinc concentration.
doi:10.1371/journal.pone.0017851.g003
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Zn
2+ to neuronal cells.
In brain chelatable Zn
2+ has been detected in presynaptic
vesicles of glutamatergic terminals and Zn
2+ ions are released from
the presynaptic site. At the postsynaptic site, Zn
2+ ions are
recruited into large macromolecular platforms within the PSD,
assembled by scaffolding molecules such as ProSAP2/Shank3 and
ProSAP1/Shank2, thus modulating the structure of the protein
meshwork underneath the postsynaptic membrane [23–26]. In
animal models, zinc exhibits antidepressant-like effects in the
forced swim test, both in mice and rats and in tail suspension test
[27–31], which are used for evaluation of antidepressant activity.
Moreover, very low doses of zinc administered together with low,
ineffective doses of imipramine or citalopram enhanced the
antidepressant-like effect in this test [27,32]. In humans,
involvement of zinc in antidepressant therapy has some clinical
correlates. It was shown that human depression is likely to be
accompanied by lower serum zinc concentrations [33–35].
Subjects suffering from major depression showed significantly
lower serum zinc levels than non-depressed controls, whereas
patients with minor depression showed intermediate zinc levels
[36]. Furthermore, a relationship between severity of depressive
symptoms and decreased serum zinc concentration in postpartum
depression was demonstrated [37] and zinc supplementation
showed a significant reduction in anger-hostility and depression-
dejection score in the Profile of Moods State (POMS) of women,
suggesting that zinc supplementation may be effective in reducing
anger and depression [38,39].
Here, we show that PLGA-based NPs can be considered as a
promising drug delivery system for the specific application of Zn
2+
to CNS neurons. Several kinds of Zn
2+ loaded or unloaded NPs
(un-modified or modified for BBB crossing) were tested both in
cultured fibroblast and primary neurons. The experiments show
that NPs themselves are not toxic to cells, even at concentrations
higher than those used for delivering Zn
2+ (Fig. 1). In fact, cell
viability is not affected below approx. 5000 mg/ml of NPs, a
concentration much higher than that needed to efficiently deliver
Zn
2+ to cells. NPs decorated with the BBB-crossing ligand (BBB-
NPs), a glycopeptide consisting of 7 aminoacids are slightly more
toxic, however not at concentrations capable of dramatically
increasing intracellular Zn
2+ levels. Nevertheless, the data
obtained should provide an important base line with respect to
the evaluation of toxicity of unloaded NPs for future experiments.
Regarding NP mediated therapies, an important question is
how, when and where NPs release their content, e.g. interstitially
or perhaps following cellular uptake. In the event of endocytosis-
Figure 4. Intracellular Zn
2+ increase over time. A) Changes in
intracellular zinc levels of HEK293 cells incubated with Zn-P-NPs or Zn-
BBB-NPs for 1–3 days (End concentration: 1 mM after complete
degradation) monitored by Zinypr-1 fluorescence (upper row). Color-
coding of Zinpyr-1 fluorescence (lower row) reveals changes in the
intracellular zinc concentration. B) Quantification intracellular zinc with
Zinypr-1 (for control and ZnCl2 reference see Fig S4.). Zinc levels in cells
treated with Zn-BBB-NPs (41 mM) are significantly higher after one day
compared to cells treated with Zn-P-NPs (22 mM). After 3 days, a final
zinc concentration of 160 mM (Zn-P-NPs) and 180 mM (Zn-BBB-NPs) was
reached. C) Hippocampal neurons were incubated with Zn-P-NPs and
Zn-BBB-NPs at 6DIV and zinc levels determined by monitoring changes
in Zinpyr-1 fluorescence (upper row and lower row heat-maps) at 7DIV
and 14DIV (End concentration: 250 mM after complete degradation). D)
After one day, Zn-P-NPs (7 mM) show a significantly lower level of
intracellular zinc compared to Zn-BBB-NPs treated cells (10 mM). After 8
days, a final zinc concentration of 48 mM (Zn-P-NPs) and 55 mM (Zn-BBB-
NPs) was reached.
doi:10.1371/journal.pone.0017851.g004
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PLoS ONE | www.plosone.org 6 March 2011 | Volume 6 | Issue 3 | e17851Figure 5. Cell type specific targeting of BBB-NPs. A) Immuncytochemistry of hippocampal neurons 14DIV stained with antibodies against
NCAM1, CD44 and MAP2. The neuronal protein NCAM1 is found to label neurons that are also immuno-positive for MAP2 (upper row of images).
CD44 positive glia are not labeled with MAP2 (lower panel). B) Fluorescent images of neuronal/glial cultures treated with TMR-labeled NPs (red)
coated with antibodies against NCAM1 or CD44. Antibodies against MAP2 and the glial specific intermediate filament associated protein GFAP
(green) were used to label neurons and glia in these cultures. Unmodified NPs (CNT-Ab-NPs) association with glial cells as well as neurons (upper
panel). NCAM1-NPs preferentially label MAP2 positive neurons (arrow, middle panel) but not GFAP positive glia. In contrast, CD44-NPs preferentially
label glial cells and a reduced labeling of neurons (arrow, lower panel) is seen. Note that the anti-CD44 ligand appears to promote NPs endocytosis. C)
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these endocytic vesicles to lysosomes could enhance release rates of
zinc due to the low pH in lysosomes (Fig. 4). To test this
hypothesis, we assessed the fate of Rhodamine labeled P-NPs and
BBB-NPs after application to cells together with FM-43 labeling
(Fig. 2D). Our results show that NPs associate with the surface of
cells and then seem to appear in an endocytic compartment
together with FM-1-43. This latter data indicates that they were
endocytosed by these cells (Fig. 2D,E). Interestingly, it seems that
the presence of BBB-ligand (glycopeptides) on the surface of BBB-
NPs enhances the number of endocytotic events compared to un-
modified NPs. The glycopeptides covering the surface of BBB-NPs
exhibit a helix-like conformation [40] postulated to contribute to
the entrance of BBB into cells by stimulating membrane curvature
and thus endocytosis. To date, no data on the effect of this
‘‘membrane curvature effect’’ are available for neurons, but a
membrane ‘‘hopping’’ type mechanism is likely [41]. Due to the
fact that NPs are polymeric and not lipid based as liposomes, it is
unlikely that they are able to fuse with cell lipid membranes.
However, NPs stay in very close contact with the cell surface and
released zinc could enter cells via specific or unspecific
transporters/ion channel systems. While feasible, the rise in cell
soma fluorescence associated with both Rhodamine-labeled BBB-
NPs and P-NPs after 7 d, indicates that at least some of these NPs
entered and released their content inside cells.
This conclusion is consistent with our results showing that BBB-
NPs can be used to elevate the intracellular Zn
2+ concentration in
a cell-based assay (Fig. 4). Given that the release rate of
encapsulated Zn
2+ in NPs (Zn-NPs) measured in vitro (Fig. 3)
showed that after approximately 3 weeks, nearly all NPs released
their content, the elevation in zinc concentration might be due to
an extracellular rise in Zn
2+ or endocytosed NPs releasing Zn
2+
inside the cell. However, in our cell-based experiments the release-
rate of zinc is faster, and perhaps cell autonomous, due to their
uptake. This is exemplified by the observed difference between
BBB-NP and P-NP, where BBB-NPs are more readily taken up by
cells, resulting in higher intracellular levels of zinc.
Since glial cells are known to clear the extracellular fluid of
substances within the brain, having NPs that selectively target
neurons or glial cells will be helpful in many ways. The extent to
which glial cells participate in psychiatric disorders is currently
only beginning to be explored, but a crucial role of glia in a wide
range of neurological disorders has long been recognized.
Although neurodegenerative disorders such as Parkinson’s disease,
Alzheimer’s disease, ALS and Huntington’s are caused by the
death of neurons, glial cells have both a positive and negative
influence on the progression of these diseases [42–45]. To
differentially target neurons and glial cells, we designed anti-
body-engineered labeled NPs using antibodies directed against an
extracellular epitope specific for neurons (NCAM1) and glial cells
(CD44). These modified NPs demonstrate that a more selective
targeting strategy can be used to enrich zinc or other drugs in a
cell type specific manner. Intriguingly, in case of CD44, this ligand
may influence endocytosis positively. Based on the results of this
study, the targeting behavior, drug release properties and
metabolism of the generated antibody-conjugated NPs can be
investigated in an in vivo model as a next step for future application
of NPs.
Conclusions
In this study we have characterized a novel nanoparticle
technology, based on PLGA NPs modified with glycopeptides
known to promote the ability of NPs to cross the BBB in vivo.W e
demonstrated that both un-modified and BBB-crossing modified
NPs, harboring substances released over time, are able to influence
neuronal cells in culture. We could show that these NPs can
efficiently deliver Zinc to cells at non-toxic concentrations. We also
provided evidence that NPs can be easily modified so that they
preferentially target specific cell populations, e.g. neurons versus
glial cells, after crossing the BBB. This strategy should improve the
delivery of drugs to the CNS. Thus, this work provides important
base line data for future in vivo application of Zn
2+ delivery by
using modified biodegradable NPs.
Materials and Methods
Materials
ZnCl2, the Zn
2+ chelator TPEN (N,N,N9,N9-tetrakis(2-pyridyl-
methyl)ethylenediamine) and Zinpyr-1 were purchased from
Sigma-Aldrich. Primary antibodies were purchased from Chemi-
con (MAP2), Abcam (GFAP), Fisher Scientific (anti-CD44, clone
OX-50), Lifespan Biosciences (NCAM1 extracellular domain) and
Synaptic Systems (Homer1). Secondary antibodies Alexa488, 568
and 647 were from Invitrogen. Poly(D,L-lactide-co-glycolide)
(PLGA RG502H) was used as received from the manufacturer
(Boehringer-Ingelheim, Ingelheim am Rhein, Germany). BBB
ligand (glycopeptides) was provided by EZ-Biolab, (Carmel, USA).
PLGA conjugated with tetramethylrhodamine (TMR-PLGA) and
conjugated with glycopeptides for BBB crossing (BBB-PLGA) was
prepared as previously described [3,6]. FM1-43FX dye was
purchased from Invitrogen. A MilliQ water system (Millipore,
Bedford, MA, USA), supplied with distilled water, provided high-
purity water (18 MV). Unless otherwise indicated, all other
chemicals were obtained from Sigma-Aldrich and were of
analytical grade.
Preparation of Nanoparticles
NPs were prepared as described in literature [46] with some
modifications in the preparation procedure. For a typical
formulation, 225 mg of ZnSO4 were dissolved in 0.25 ml of
distilled water and emulsified in 2.5 ml of CH2Cl2 (containing
50 mg of a mixture of PLGA 503 H and BBB-PLGA (80:20 w/w)
(with or without 5–10 mg TMR-PLGA) by sonication over an ice
bath using a probe sonicator (Misonix, MicrosonTM Ultrasonic
Cell Disruptor XL, Opto-lab, Concordia, Mo, Italy) at 60 W
output for 45 sec. The resulting primary emulsion was added to
5 ml distilled water containing PVA 1% (15000 MW, Sigma-
Aldrich) and was sonicated for 60 sec at 100 W amplitude over an
ice bath to form the double emulsion. Organic solvent was
removed by stirring at room temperature for at least 1 h and
finally purified by Hi-Speed Refrigerated Centrifugation (Beck-
man J21) at 14000 rpm for 10 min. Alternatively, we also obtained
unloaded NPs (P-NPs and BBB-NPs) by omission of drugs within
the inner aqueous phase. With this procedure we were able to
obtain Zn-P-NPs (when using un-modified PLGA) and Zn-BBB-
NPs (when BBB-PLGA was used). In conclusion, labeled (TMR-
Quantification of percent colocalization (yellow) between NPs (red) and MAP2 (green) or GFAP (green) (n=10). CD44-NPs show significantly higher
colocalization with GFAP compared to NCAM1-NPs and CNT-AB-NPs. In contrast, NCAM1-NPs show significantly higher colocalization with MAP2
compared to GFAP and CNT-Ab-NPs. CD44-NPs and NCAM1-NPs show similar colocalization values like CNT-Ab-NPs for MAP2 (CD44-NPs) and GFAP
(NCAM1-NPs).
doi:10.1371/journal.pone.0017851.g005
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to be tested in cell cultures.
Antibody engineered NPs were prepared starting from PLGA
NPs, obtained as described before for P-NPs, and applying well
known methodologies for Ab-surface engineering of NPs [47].
Briefly, in the presence of EDC (1-Ethyl-3-(3-dimethylaminopro-
pyl)-carbodiimide, EDC) (170 mg) and N–Hydroxy-succinimide
(NHS, 30 mg) to conjugate the free primary amine groups on the
NPs surface with the carboxylic groups on the antibody molecules,
desired amount of TMR-labeled P-NPs (50 mg) was suspended
and stirred at RT for 1.30 hr in MES (2-(N-morpholino)ethane-
sulfonic acid, Sigma Aldrich) buffer with designated volume of
Anti-NCAM1 Ab (50 ml of a 1 mg/mL stock solution) or Anti-
CD44 Ab (50 ml of a 0.5 mg/mL stock solution) stock solution or a
corresponding amount of buffer solution, in order to obtain
respectively Anti-NCAM1-NPs, Anti-CD44 NPs and control
group (CNT-Ab-NPs). After the reaction, the suspension of the
engineered NPs were collected by centrifugation and further
washed twice by distilled water for purification. Some amount of
engineered NPs was re-suspended in ultrapure water for further
characterization, while other NPs were lyophilized to prepare
stocks (trealose was added as cryoprotector).
NPs characterization
All the batches of NPs were characterized in their surface
properties, size and shape. All the data collected (data not shown)
demonstrated that the surface engineering (with Ab) of NPs or the
loading with Zn did not affect the morphological features of the
NPs, all having similar dimensions and shape. A scanning electron
microscope (SEM) (XL-40 Philips, Eindhoven, The Netherlands)
(610,000) was used to evaluate the morphology of NPs. Before the
SEM analysis, the samples were coated under argon atmosphere
with a 10 nm layer of palladium gold (Emitech K550 Supper
Coated, Emitech LTD, U.K.). NPs in distilled water were
analyzed for particle size and zeta potential (z-p) by photon
correlation spectroscopy and laser Doppler anemometry using a
Zetasizer Nano ZS (Malvern, UK; Laser 4 mW He–Ne, 633 nm,
Laser attenuator Automatic, transmission 100% to 0.0003%,
Detector Avalanche photodiode, Q.E..50% at 633 nm,
T=25uC). The results were normalized with respect to a
polystyrene standard solution.
As scientifically established in literature, [47] the surface
engineering of NPs (Anti-NCAM1 or Anti-CD44 NPs) was
demonstrated by Electron Spectroscopy for Chemical Analysis
(ESCA) study showing the presence of atoms (N) present on the
surface of antibody-engineered NPs and thus proof of success of
the surface engineering procedure. ESCA was performed on a 04-
153 X-ray source analysis system (PHI, Uvalca-PHI, Tokyo,
Japan) and an EA11 hemispherical electron analyzer (Leybold
Optics, Germany), using MgKa1,2 radiations. The spectra were
recorded in fixed retardation ratio (FAT) mode with 190 eV pass
energy. The pressure in the sample analysis chamber was ca.
1029 mbar. The data were acquired and processed using the
RBD AugerScan 2. 1H-HRMAS NMR spectra were recorded on
a Bruker Avance 400 instrument; D2O was added to the sample,
which was then spun at 4000 Hz. All experiments were recorded
at RT.
Determination of NPs content
10 mg of NPs (both batches of BBB and plain NPs) loaded with
ZnSO4 were dissolved in 1 ml of DCM and 5 ml of milliQ water
were added to the organic solution. The organic solvent was
removed by stirring at room temperature for at least 3 h and finally
theaqueoussolution was filtered througha syringefilterto eliminate
the polymer insoluble in water. The final volume of the aqueous
solution was adjusted to 25 ml with distilled water and 1 ml of this
solution was diluted to 25 ml. The final aqueous solution was
analyzed through atomic absorption spectrophotometry. A 5 mM
Zn
2+ containing stock solution (12.5 mg NPs/ml) was prepared.
The results shown represent the mean of at least 3 experiments.
Zn release from NP
10 mg of Zn-NPs (both BBB-NPs and P-NPs) loaded with
ZnSO4 were suspended in 1 ml of milliQ water into a dialysis
membrane tube (3500 MW cut-off). The dialysis membrane tube
was then placed into a becker containing the release medium
(25 ml of milliQ water), which was stirred continuously and
maintained at 37uC. At determined intervals, 100 ml of release
medium solution was collected and then replaced with 100 mlo f
fresh milliQ water. This sample was diluted to 25 ml with Milli-Q
water and then the solution was analyzed with atomic absorption
spectrophotometry. The results shown represent the mean of at
least 3 experiments.
Hippocampal culture from rat brain
The preparation of hippocampal cultures was performed
essentially as described by Goslin et al. [48] withsome modifications
as detailed in Dresbach et al. [49]. Cell culture experiments of
hippocampal primary neurons from rat (embryonic day-18; E18)
were performed as described previously [50]. After preparation the
hippocampal neurons were seeded on poly-l-lysine (0.1 mg/ml;
Sigma-Aldrich, Steinheim) glas coverlslips. Cells were grown in
Neurobasal medium (Invitrogen), complemented with B27 supple-
ment (Invitrogen), 0.5 mM L-Glutamine (Invitrogen) and 100 U/
ml penicillin/streptomycin (Invitrogen) and maintained at 37uCi n
5% CO2. All animal experiments were performed in compliance
withthe guidelines for the welfare of experimental animals issued by
the Federal Government of Germany and the National Institutes of
Health. All of the experiments were conducted in strict compliance
with APLAC approved animal protocols from Stanford University
(protocol # 14607) and by the local ethics committee (Ulm
University) ID Number: O.103.
Immunhistochemistry
For immunofluorescence, HEK293 cells and primary cultures
were fixed with 4% paraformaldehyde (PFA)/1.5% sucrose/PBS
at 4uC for 20 min and processed for immunohistochemistry. After
washing 365 min with 16PBS at RT, blocking was performed
with 0.5% cold fish gelatine (Sigma) and 0.1% Ovalbumin
(Sigma)/16 PBS for 30 min at RT and the cells were washed
again 36 5 min with 16 PBS at RT, followed by the primary
antibody at 4uC overnight. After a 365 min washing-step with 16
PBS, incubation with the second antibody coupled to Alexa488,
Alexa568, Alexa647 or TexasRed (Molecular Probes) for 1 h
followed. The cells were washed again in 16PBS for 10 min and
5 min with aqua bidest and mounted in Vecta Shield mounting
medium with or without DAPI (for staining the nucleus) for
fluorescence microscopy. To test cell viability, the number of
DAPI positive nuclei and neurons was counted from 10 optic fields
for each condition.
Zinc staining
Zn-P-NPs and Zn-BBB-NPs were suspended in Neurobasal
Medium (+Glutamine +B 2 7 )a n da p p l i e dt oc e l l s .A sC o n t r o l ,
different solutions with defined Zn
2+ concentration were used. An
aliquot of Zinpyr-1 DMSO stock solution (5 mM) was diluted to a
final concentration of 1–5 mM in culture medium and the cells were
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washed in Ca/Mg Phosphate buffered saline and used for confocal
mi c r o s co p y .I ma g e sw e r et a k e nw i t ht h es a m ee x p o s u r et i mea n dg re y
values quantified using ImageJ v.1.44e. For quantification, the basic
fluorescenceofthemedium(greyvalue)wasmeasuredandsubtracted
from the grey values of a defined ZnCl2 solution as well as the Zn-P-
NPs and Zn-BBB-NPs-suspension. The ratio of the normalized
ZnCl2 solution to the NPs suspension determined the final Zn
2+
concentration. Measurements were performed three times for each
time point using different exposure times.
Measurement of Zn
2+ concentrations
The zinc-concentration of hippocampal cell culture medium
was measured by Plasma-Massspectrometry (ICP-MS) at the
‘‘Spurenanalytisches Laboratorium Dr. Baumann’’ (Maxhu ¨tte-
Haidhof, Germany).
Statistical analysis
Images were taken with a spinning disk confocal microscope
(Zeiss) using MetaMorph (Universal Imaging, Downing-town, PA)
software. Quantification of fluorescence data was performed using,
Image J 1.44e software with JACoP plugin. Statistical analysis in
this paper was performed using Microsoft Excel for Macintosh and
data were tested for significance using two-tailed, Student’s t-test
followed by ANOVA and p-values ,0.05 were stated as significant
(,0.05*; ,0.01**; ,0.001***).
Supporting Information
Figure S1 Cells treated with unloaded P-NPs and BBB-
NPs exhibited no difference in their morphology and
synapse density compared to untreated cells. A) Dendrite
branching was measured using MAP2 stained neurons. The
dendritic complexity index (DCI) [13] was calculated based on the
equation: [DCI=(# of prim. Dendrites * 1+# of sec. Dendrites *
2+# of tert. Dendrites * 3)/(# of prim.+sec.+tert. Dendrites)]. B)
The number of synapses per unit length of dendrites was evaluated
using Homer1 as postsynaptic marker and Bassoon as presynaptic
marker. The number of Homer1/Bassoon colocalizing signals per
10 mm dendrite length is shown.
(EPS)
Figure S2 A) Overview of images of HEK293 (upper panel) and
neurons (lower panel) shown in detail in Figure 2B. White squares
indicate regions shown in Figure 2B. Bottom row of images in each
panel are heat maps revealing regional differences in zinc levels. B)
Fluorescent images of neurons 1, 2, 6 and 7 days following the
addition of Rhodamine conjugated BBB-NPs. After 7 days the
Rhodamine-BBB-NPs exhibit a diffuse pattern suggesting that
endocytosed BBB-NPs are partially released into the cell soma.
(EPS)
Figure S3 Prolonged exposure to high free Zn
2+ concen-
tration causes cell death in HEK293 cells and hippo-
campal neurons. To determine the range of viable intracellular
Zn
2+ concentrations and their limit for toxicity, we supplemented cell
cultures with increasing Zn
2+ concentrations for 8 h. The results
show that neurons (upper row) are more sensitive to free Zn
2+
compared to HEK293 cells (lower row). After supplementation of the
medium with a concentration of 80 mMZ n
2+ and higher, neurons
undergo cell death visible through cell fractionation, which leads to a
loss of intracellular fluid and thus Zn
2+ (full arrows). Additionally,
condensed and fractionated nuclei appear (open arrow). HEK293
cells undergo cell death at Zn
2+ concentrations higher then 160 mM,
visible through cells rounding up due to a loss of surface adhesion.
(EPS)
Figure S4 Supplementation of HEK293 cells (left panel)
and hippocampal neurons (right panel) with ZnCl2 was
used as reference for the evaluation of zinc concentra-
tions (Fig. 4). The brightness of the Zinpyr-1 signal of untreated
cells and cells treated with a defined amount (30 mM) ZnCl2 was
used to evaluate the increase in zinc concentration by Zn-P-NPs
and Zn-BBB-NPs (Fig. 4). The final zinc concentration was
calculated using grey values of Zinpyr-1 fluorescence. Background
fluorescence of untreated neurons was measured and cells treated
with 30 mM ZnCl2 used as reference. HEK293 cells were
supplemented with ZnCl2 at DIV0 and the zinc concentration
was evaluated after 1 and 3 days. Hippocampal neurons were
supplemented with ZnCl2 at DIV6 and the zinc concentration was
evaluated at DIV7 and DIV14.
(EPS)
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